[Tanvex-KY] Announcement of the board's resolution to convene the 2026 Annual Shareholders' Meeting (with added agenda items)
Tanvex BioPharma's board resolved to hold its AGM on June 4, 2026. Key agenda items include a deficit compensation plan and a private placement for capital injection.
📋 Article Processing Timeline
- 📰 Published: April 22, 2026 at 09:00
- 🔍 Collected: April 23, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: April 23, 2026 at 12:39 (4h 39m after Collected)
1. Date of the board of directors' resolution: 2026/04/22
2. Date of the shareholders' meeting: 2026/06/04
3. Location: 8F, No. 11, Zhongshan S. Rd., Zhongzheng Dist., Taipei City (Chang Yung-Fa Foundation International Convention Center)
4. Meeting format: Physical shareholders' meeting
5. Cause for convening I: Report items
(1) 2025 Business Report.
(2) 2025 Audit Committee Review Report.
(3) Communication report between Audit Committee and Chief Internal Auditor.
(4) 2025 Sound Business Plan execution report.
6. Cause for convening II: Ratification items
(1) 2025 Business Report and Consolidated Financial Statements.
(2) 2025 Deficit Compensation Proposal.
7. Cause for convening III: Discussion items
(1) Amendment to the "Procedures for Acquisition or Disposal of Assets".
(2) Amendment to the "Procedures for Endorsement and Guarantee".
(3) Proposal to issue common shares and/or domestic/overseas unsecured convertible corporate bonds via private placement.
8. Cause for convening IV: Election items
(1) By-election of one Independent Director.
9. Cause for convening V: Other items
(1) Proposal to release the prohibition on directors from participation in competitive business.
10. Extemporary motions:
11. Start date of suspension of transfer: 2026/04/06
12. End date of suspension of transfer: 2026/06/04
13. Other matters: E-voting period is from May 5 to June 1, 2026.
2. Date of the shareholders' meeting: 2026/06/04
3. Location: 8F, No. 11, Zhongshan S. Rd., Zhongzheng Dist., Taipei City (Chang Yung-Fa Foundation International Convention Center)
4. Meeting format: Physical shareholders' meeting
5. Cause for convening I: Report items
(1) 2025 Business Report.
(2) 2025 Audit Committee Review Report.
(3) Communication report between Audit Committee and Chief Internal Auditor.
(4) 2025 Sound Business Plan execution report.
6. Cause for convening II: Ratification items
(1) 2025 Business Report and Consolidated Financial Statements.
(2) 2025 Deficit Compensation Proposal.
7. Cause for convening III: Discussion items
(1) Amendment to the "Procedures for Acquisition or Disposal of Assets".
(2) Amendment to the "Procedures for Endorsement and Guarantee".
(3) Proposal to issue common shares and/or domestic/overseas unsecured convertible corporate bonds via private placement.
8. Cause for convening IV: Election items
(1) By-election of one Independent Director.
9. Cause for convening V: Other items
(1) Proposal to release the prohibition on directors from participation in competitive business.
10. Extemporary motions:
11. Start date of suspension of transfer: 2026/04/06
12. End date of suspension of transfer: 2026/06/04
13. Other matters: E-voting period is from May 5 to June 1, 2026.